Related Experiment Video
Updated: Aug 27, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
An adeno-associated virus vector-based intracellular peptide delivery system for treating hepatocellular carcinoma
Bo Qie1, Jiale Li1, Mengjie Wan1
1School of Nano Technology and Nano Bionics, University of Science and Technology of China, Hefei 230026, China; CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
Abstract:
The inactivation of the p53 protein explains the incidence of approximately 50% of hepatocellular carcinoma (HCC) cases. As a key negative regulator, murine double minute 2 (MDM2) mediates the degradation of p53 protein. Therefore, targeting the p53-MDM2 protein-protein interaction (PPI) has become a promising therapeutic strategy for cancers with wild-type p53 (wtp53). The p53-MDM2 interaction inhibitor (PMI) has shown potential to restore p53 function by disrupting its interaction with MDM2, however, the therapeutic efficacy of the PMI is compromised due to its instability and low cell membrane permeability. In this study, a peptide gene delivery system, sc-SUR(447)-GFP-PMI-4, was developed using self-complementary adeno-associated virus (scAAV). This system enables tumor-specific expression of tetrameric PMI peptides under the control of the survivin promoter. The results revealed that PMI-4 genes delivered by sc-SUR(447)-GFP-PMI-4 were selectively expressed in tumor cells both in vitro and in vivo. The system demonstrated potential as a safe and effective therapeutic agent in an orthotopic xenograft hepatocellular carcinoma (HCC) model where it inhibited the degradation of the p53 protein. In conclusion, the study introduced an innovative systemic peptide delivery system in which peptides delivered by scAAVs effectively block tumorigenic intracellular PPIs, providing a promising strategy for cancer therapy.
Insights
A novel gene delivery system using self-complementary adeno-associated virus (scAAV) effectively targets hepatocellular carcinoma (HCC). This system delivers peptide inhibitors to block p53 degradation, offering a promising cancer therapy strategy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Hepatocellular carcinoma (HCC) involves p53 protein inactivation in about 50% of cases.
- Murine double minute 2 (MDM2) protein degrades p53, making the p53-MDM2 interaction a therapeutic target.
- Existing p53-MDM2 interaction inhibitors (PMIs) face challenges with stability and cell permeability.
Purpose of the Study:
- To develop a novel gene delivery system for tumor-specific expression of peptide inhibitors.
- To evaluate the efficacy of this system in restoring p53 function and inhibiting HCC growth.
- To establish a safe and effective therapeutic strategy for cancers with wild-type p53 (wtp53).
Main Methods:
- Development of a self-complementary adeno-associated virus (scAAV) based system (sc-SUR(447)-GFP-PMI-4).
- Tumor-specific expression of tetrameric PMI peptides driven by the survivin promoter.
- In vitro and in vivo assessment in an orthotopic xenograft HCC model.
Main Results:
- The scAAV system achieved selective expression of PMI-4 genes in tumor cells.
- The system effectively inhibited p53 protein degradation in HCC models.
- Demonstrated potential as a safe and effective therapeutic agent in preclinical HCC models.
Conclusions:
- The study presents an innovative systemic peptide delivery system using scAAVs.
- Delivered peptides successfully block tumorigenic intracellular protein-protein interactions (PPIs).
- This approach offers a promising new strategy for cancer therapy, particularly for HCC.
More Related Videos
08:55Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
